US based endovascular company AngioScore has introduced its new 100mm length AngioSculpt PTA scoring balloon catheters, designed to treat complex lesions in patients with peripheral artery disease (PAD) below the knee (BTK), including critical limb ischemia (CLI) and infra-popliteal PAD.

With diameters of 2.0mm, 2.5mm, 3.0mm and 3.5mm, the balloon catheters feature nitinol-scoring elements that offer unique circumferential scoring of plaque, resulting in precise and predictable luminal enlargement across a wide range of lesion types.

The longer AngioSculpt catheters also have the ability to achieve a very low rate of dissection, potentially minimising the need to perform adjunctive stenting, according to the company.

AngioScore president and CEO Thomas Trotter said the peripheral artery disease market is a rapidly growing segment of the interventional cardiovascular market.

“With diameters of 2.0mm, 2.5mm, 3.0mm and 3.5mm, the balloon catheters feature nitinol-scoring elements that offer unique circumferential scoring of plaque, resulting in precise and predictable luminal enlargement across a wide range of lesion types.”

“Over a million percutaneous peripheral procedures are now being performed annually worldwide, and the PAD market continues to demonstrate significant growth due to improved diagnosis and the increasing prevalence of important risk factors such as adult onset diabetes mellitus,” Thomas said.

“We believe that the AngioSculpt line of scoring balloon catheters is particularly useful in treating this very challenging and serious disease.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new catheters are also FDA-approved for use in the dilatation of lesions in the iliac, femoral, iliofemoral, popliteal, infra-popliteal, and renal arteries, as well as for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

AngioScore said the AngioSculpt catheters are not labelled for use in the coronary or neuro-vasculature.